204 related articles for article (PubMed ID: 30129371)
1. Stargardt macular dystrophy and evolving therapies.
Hussain RM; Ciulla TA; Berrocal AM; Gregori NZ; Flynn HW; Lam BL
Expert Opin Biol Ther; 2018 Oct; 18(10):1049-1059. PubMed ID: 30129371
[TBL] [Abstract][Full Text] [Related]
2. Pharmacotherapy of retinal disease with visual cycle modulators.
Hussain RM; Gregori NZ; Ciulla TA; Lam BL
Expert Opin Pharmacother; 2018 Apr; 19(5):471-481. PubMed ID: 29542350
[TBL] [Abstract][Full Text] [Related]
3. Complement modulation in the retinal pigment epithelium rescues photoreceptor degeneration in a mouse model of Stargardt disease.
Lenis TL; Sarfare S; Jiang Z; Lloyd MB; Bok D; Radu RA
Proc Natl Acad Sci U S A; 2017 Apr; 114(15):3987-3992. PubMed ID: 28348233
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutics for Stargardt disease.
Lu LJ; Liu J; Adelman RA
Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1057-1062. PubMed ID: 28285324
[TBL] [Abstract][Full Text] [Related]
5. Visual cycle modulators versus placebo or observation for the prevention and treatment of geographic atrophy due to age-related macular degeneration.
Yeong JL; Loveman E; Colquitt JL; Royle P; Waugh N; Lois N
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013154. PubMed ID: 33331670
[TBL] [Abstract][Full Text] [Related]
6. Expression of ABCA4 in the retinal pigment epithelium and its implications for Stargardt macular degeneration.
Lenis TL; Hu J; Ng SY; Jiang Z; Sarfare S; Lloyd MB; Esposito NJ; Samuel W; Jaworski C; Bok D; Finnemann SC; Radeke MJ; Redmond TM; Travis GH; Radu RA
Proc Natl Acad Sci U S A; 2018 Nov; 115(47):E11120-E11127. PubMed ID: 30397118
[TBL] [Abstract][Full Text] [Related]
7. Complement inhibition as a therapeutic strategy in retinal disorders.
Kassa E; Ciulla TA; Hussain RM; Dugel PU
Expert Opin Biol Ther; 2019 Apr; 19(4):335-342. PubMed ID: 30686077
[TBL] [Abstract][Full Text] [Related]
8. [New possibilities in the treatment of Stargardt disease].
Zhorzholadze NV; Sheremet NL; Tanas AS; Strelnikov VV
Vestn Oftalmol; 2020; 136(4. Vyp. 2):333-343. PubMed ID: 32880159
[TBL] [Abstract][Full Text] [Related]
9. Can Vitamin A be Improved to Prevent Blindness due to Age-Related Macular Degeneration, Stargardt Disease and Other Retinal Dystrophies?
Saad L; Washington I
Adv Exp Med Biol; 2016; 854():355-61. PubMed ID: 26427432
[TBL] [Abstract][Full Text] [Related]
10. Gene Therapy of ABCA4-Associated Diseases.
Auricchio A; Trapani I; Allikmets R
Cold Spring Harb Perspect Med; 2015 Jan; 5(5):a017301. PubMed ID: 25573774
[TBL] [Abstract][Full Text] [Related]
11. Membrane Attack Complex Mediates Retinal Pigment Epithelium Cell Death in Stargardt Macular Degeneration.
Ng ESY; Kady N; Hu J; Dave A; Jiang Z; Pei J; Gorin MB; Matynia A; Radu RA
Cells; 2022 Nov; 11(21):. PubMed ID: 36359858
[TBL] [Abstract][Full Text] [Related]
12. A1120, a nonretinoid RBP4 antagonist, inhibits formation of cytotoxic bisretinoids in the animal model of enhanced retinal lipofuscinogenesis.
Dobri N; Qin Q; Kong J; Yamamoto K; Liu Z; Moiseyev G; Ma JX; Allikmets R; Sparrow JR; Petrukhin K
Invest Ophthalmol Vis Sci; 2013 Jan; 54(1):85-95. PubMed ID: 23211825
[TBL] [Abstract][Full Text] [Related]
13. Rescue of the Stargardt phenotype in Abca4 knockout mice through inhibition of vitamin A dimerization.
Charbel Issa P; Barnard AR; Herrmann P; Washington I; MacLaren RE
Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8415-20. PubMed ID: 26106163
[TBL] [Abstract][Full Text] [Related]
14. Multimodal imaging and multifocal electroretinography demonstrate autosomal recessive Stargardt disease may present like occult macular dystrophy.
Sisk RA; Leng T
Retina; 2014 Aug; 34(8):1567-75. PubMed ID: 24743636
[TBL] [Abstract][Full Text] [Related]
15. Gene therapy for Stargardt disease associated with ABCA4 gene.
Han Z; Conley SM; Naash MI
Adv Exp Med Biol; 2014; 801():719-24. PubMed ID: 24664763
[TBL] [Abstract][Full Text] [Related]
16. Impaired cathepsin D in retinal pigment epithelium cells mediates Stargardt disease pathogenesis.
Ng ESY; Hu J; Jiang Z; Radu RA
FASEB J; 2024 Jun; 38(11):e23720. PubMed ID: 38837708
[TBL] [Abstract][Full Text] [Related]
17. Stargardt disease: clinical features, molecular genetics, animal models and therapeutic options.
Tanna P; Strauss RW; Fujinami K; Michaelides M
Br J Ophthalmol; 2017 Jan; 101(1):25-30. PubMed ID: 27491360
[TBL] [Abstract][Full Text] [Related]
18. Asymmetric Inter-Eye Progression in Stargardt Disease.
Lambertus S; Bax NM; Groenewoud JM; Cremers FP; van der Wilt GJ; Klevering BJ; Theelen T; Hoyng CB
Invest Ophthalmol Vis Sci; 2016 Dec; 57(15):6824-6830. PubMed ID: 28002570
[TBL] [Abstract][Full Text] [Related]
19. [Clinical Tests Testing New Therapies for Stargardt Disease].
Kousal B; Ďuďáková Ľ; Hlavatá L; Lišková P
Cesk Slov Oftalmol; 2016 Feb; 72(1):293-7. PubMed ID: 27041285
[TBL] [Abstract][Full Text] [Related]
20. C20-D3-vitamin A slows lipofuscin accumulation and electrophysiological retinal degeneration in a mouse model of Stargardt disease.
Ma L; Kaufman Y; Zhang J; Washington I
J Biol Chem; 2011 Mar; 286(10):7966-7974. PubMed ID: 21156790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
